# Óscar Arrieta

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/oscar-arrieta/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,045 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 60 |
| i10-index | 269 |
| Last Known Institution | Instituto Nacional de Cancerología |
| OpenAlex ID | https://openalex.org/A5035063101 |
| ORCID iD | https://orcid.org/0000-0002-1164-3779 |
| Works | 811 |

## Researcher papers

- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors](https://scholariq.org/papers/a-phase-ii-study-of-epigenetic-therapy-with-hydralazine-and-magnesium-valproate/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Instituto Nacional de Cancerología](https://scholariq.org/institutions/instituto-nacional-de-cancerologia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.